Xu Ke, Xiong Wenhua, Zhao Shoujun, Wang Bin
Orthopedics Centre, Ningbo No. 2 Hospital, Ningbo, Zhejiang 315010, P.R. China.
Oncol Lett. 2019 Sep;18(3):3342-3348. doi: 10.3892/ol.2019.10666. Epub 2019 Jul 25.
MicroRNAs (miRNAs) have been demonstrated to be involved in tumor progression of various human malignancies. The purpose of this study was to investigate the expression patterns and prognostic value of microRNA-106b (miR-106b) in osteosarcoma (OS) and to examine its functional role in OS progression. Reverse transcription-quantitative PCR (RT-qPCR) was used to estimate the expression of miR-106b in OS tissues and cells. The prognostic value of miR-106b in OS was evaluated by plotting Kaplan-Meier survival curves and performing Cox analyses. Cell experiments were carried out to examine the effects of miR-106b on OS cell proliferation, migration, and invasion. The expression of miR-106b was elevated in both OS tissues and cells compared with the expression in normal control tissues and cells (P<0.001). miR-106b expression was associated with metastasis (P=0.028) and Tumor-Node-Metastasis stage (P=0.017). Patients with high miR-106b expression levels had a poorer overall survival rate compared with those with low miR-106b expression levels (log-rank P=0.001). Multivariate Cox analyses indicated that miR-106b expression was an independent prognostic factor for patients with OS (hazard ratio=2.769; 95% confidence interval=1.369-5.599; P=0.005). The results of cell experiments implied that the upregulation of miR-106b could promote OS cell proliferation, migration and invasion, whereas the downregulation of miR-106b could suppress these functions (P<0.05). Taken together, this study's results indicated that the overexpression of miR-106b is associated with a poor prognosis for patients with OS and that overexpression promotes OS cell proliferation, migration, and invasion. This study may provide a novel prognostic biomarker and a candidate therapeutic target for OS treatment.
微小RNA（miRNA）已被证明参与多种人类恶性肿瘤的肿瘤进展。本研究的目的是调查微小RNA-106b（miR-106b）在骨肉瘤（OS）中的表达模式和预后价值，并研究其在OS进展中的功能作用。采用逆转录定量PCR（RT-qPCR）检测miR-106b在OS组织和细胞中的表达。通过绘制Kaplan-Meier生存曲线和进行Cox分析来评估miR-106b在OS中的预后价值。进行细胞实验以检测miR-106b对OS细胞增殖、迁移和侵袭的影响。与正常对照组织和细胞中的表达相比，miR-106b在OS组织和细胞中的表达均升高（P<0.001）。miR-106b表达与转移（P=0.028）和肿瘤-淋巴结-转移分期（P=0.017）相关。与miR-106b表达水平低的患者相比，miR-106b表达水平高的患者总生存率较差（对数秩检验P=0.001）。多变量Cox分析表明，miR-106b表达是OS患者的独立预后因素（风险比=2.769；95%置信区间=1.369-5.599；P=0.005）。细胞实验结果表明，miR-106b的上调可促进OS细胞增殖、迁移和侵袭，而miR-106b的下调则可抑制这些功能（P<0.05）。综上所述，本研究结果表明，miR-106b的过表达与OS患者的不良预后相关，且过表达促进OS细胞增殖、迁移和侵袭。本研究可能为OS治疗提供一种新的预后生物标志物和候选治疗靶点。
